In last trading session, Macrogenics Inc (NASDAQ:MGNX) saw 0.38 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $1.48 trading at -$0.06 or -3.90% at ring of the bell on the day assigns it a market valuation of $93.37M. That closing price of MGNX’s stock is at a discount of -289.86% from its 52-week high price of $5.77 and is indicating a premium of 33.11% from its 52-week low price of $0.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.84 million shares which gives us an average trading volume of 1.24 million if we extend that period to 3-months.
For Macrogenics Inc (MGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.50. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.38 in the current quarter.
Macrogenics Inc (NASDAQ:MGNX) trade information
Macrogenics Inc’s shares saw a change of -72.52% in year-to-date performance and have moved -8.07% in past 5-day. Macrogenics Inc (NASDAQ:MGNX) showed a performance of 8.03% in past 30-days. Number of shares sold short was 5.53 million shares which calculate 3.17 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 40.8% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -35.14% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.14% for stock’s current value.
Macrogenics Inc (MGNX) estimates and forecasts
This year revenue growth is estimated to fall -38.86% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 28.06M for the same. And 6 analysts are in estimates of company making revenue of 23.31M in the next quarter. Company posted 10.8M and 110.71M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.47% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -55.61% while estimates for its earnings growth in next 5 years are of -25.45%.
Macrogenics Inc (NASDAQ:MGNX)’s Major holders
Insiders are in possession of 3.01% of company’s total shares while institution are holding 73.84 percent of that, with stock having share float percentage of 76.14%. Investors also watch the number of corporate investors in a company very closely, which is 73.84% institutions for Macrogenics Inc that are currently holding shares of the company. BELLEVUE GROUP AG is the top institutional holder at MGNX for having 9.94 million shares of worth $42.25 million. And as of 2024-06-30, it was holding 15.8662 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 6.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.5749 of outstanding shares, having a total worth of $25.5 million.
